Work

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

Year: 2015

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v126.23.1280.1280

Authors: Jennifer E Amengual, Lichtenstein Renee, Celeste Rojas, Kelly Zullo, Maximilian Lombardo, Emily Lichtenstein, Ellen Neylon, Changchun Deng, Ahmed Sawas, Bijal D Shah, Catherine Wheeler, Simon S Jones, Owen A. O'Connor

Institutions: Columbia University Irving Medical Center, Moffitt Cancer Center, Acetylon Pharmaceuticals (United States)

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2576371571

FWCI:

Cites:

Cited by:

Related to: 10